TG Therapeutics (TGTX) Misses Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2016 Financial Results
November 7, 2016 7:30 AM ESTNEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2016 and recent company developments.
Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, stated, "The third quarter was a pivotal one for the company, particularly with the amendment of the GENUINE Phase 3 trial that will enable the rapid conclusion of the study while also maintaining the possibility for accelerated approval for TG-1101 in combination with ibrutinib. Importantly, with GENUINE enrollment wrapping up, we can dedicate our resources... More
TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2016 Financial Results and Business Update
November 3, 2016 4:00 PM EDTNEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, November 7, 2016 at 8:30am ET to discuss results for the third quarter of 2016 and provide a business outlook for the remainder of the year. Â Michael S. Weiss, Executive Chairman and Interim Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.),... More
TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 58th American Society of Hematology Annual Meeting
November 3, 2016 9:15 AM EDTNEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that updated data for TGR-1202, the Companys once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Companys novel glycoengineered anti-CD20 monoclonal antibody, have been selected for presentation at the upcoming 58th American Society of Hematology (ASH) annual meeting, to be held December 3-6, 2016, at the San Diego Convention Center in San Diego, California.
We are looking forward to an exciting ASH conference as we continue to present data on the differentiation between TGR-1202 and the first generation PI3K delta... More
